Several monoclonal antibodies are designed to engage ADCC in cancer therapy. Examples include Rituximab (used in non-Hodgkin lymphoma), Trastuzumab (used in HER2-positive breast cancer), and Cetuximab (used in colorectal cancer). These antibodies target specific antigens such as CD20, HER2, and EGFR, respectively, on cancer cells.
